Anti-KMT5C monoclonal antibody
Pre-made anti-KMT5C monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to KMT5C/KMT5C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T68490-Ab-1/ GM-Tg-hg-T68490-Ab-2 | Anti-Human KMT5C monoclonal antibody | Human |
GM-Tg-rg-T68490-Ab-1/ GM-Tg-rg-T68490-Ab-2 | Anti-Rat KMT5C monoclonal antibody | Rat |
GM-Tg-mg-T68490-Ab-1/ GM-Tg-mg-T68490-Ab-2 | Anti-Mouse KMT5C monoclonal antibody | Mouse |
GM-Tg-cynog-T68490-Ab-1/ GM-Tg-cynog-T68490-Ab-2 | Anti-Cynomolgus/ Rhesus macaque KMT5C monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T68490-Ab-1/ GM-Tg-felg-T68490-Ab-2 | Anti-Feline KMT5C monoclonal antibody | Feline |
GM-Tg-cang-T68490-Ab-1/ GM-Tg-cang-T68490-Ab-2 | Anti-Canine KMT5C monoclonal antibody | Canine |
GM-Tg-bovg-T68490-Ab-1/ GM-Tg-bovg-T68490-Ab-2 | Anti-Bovine KMT5C monoclonal antibody | Bovine |
GM-Tg-equg-T68490-Ab-1/ GM-Tg-equg-T68490-Ab-2 | Anti-Equine KMT5C monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T68490-Ab-1/ GM-Tg-hg-T68490-Ab-2; GM-Tg-rg-T68490-Ab-1/ GM-Tg-rg-T68490-Ab-2; GM-Tg-mg-T68490-Ab-1/ GM-Tg-mg-T68490-Ab-2; GM-Tg-cynog-T68490-Ab-1/ GM-Tg-cynog-T68490-Ab-2; GM-Tg-felg-T68490-Ab-1/ GM-Tg-felg-T68490-Ab-2; GM-Tg-cang-T68490-Ab-1/ GM-Tg-cang-T68490-Ab-2; GM-Tg-bovg-T68490-Ab-1/ GM-Tg-bovg-T68490-Ab-2; GM-Tg-equg-T68490-Ab-1/ GM-Tg-equg-T68490-Ab-2 |
Products Name | Anti-KMT5C monoclonal antibody |
Format | mab |
Target Name | KMT5C |
Protein Sub-location | Introcelluar Protein |
Category of antibody | Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-KMT5C monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T68490-Ag-1 | Recombinant multi-species KMT5C/ SUV420H2/ Suv4-20h2 protein |
Target information
Target ID | GM-T68490 |
Target Name | KMT5C |
Gene ID | 84787,232811,308345,699963,484295,101091322,519777,100055743 |
Gene Symbol and Synonyms | KMT5C,Suv4-20h2,SUV420H2 |
Uniprot Accession | Q86Y97,P0C2N6 |
Uniprot Entry Name | KMT5C_HUMAN,KMT5C_RAT |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000133247 |
Target Classification | N/A |
The target: KMT5C, gene name: KMT5C, also named as SUV420H2, Suv4-20h2. SUV420H2 and the related enzyme SUV420H1 (MIM 610881) function as histone methyltransferases that specifically trimethylate nucleosomal histone H4 (see MIM 602822) on lysine-20 (K20) (Schotta et al., 2004 [PubMed 15145825]).[supplied by OMIM, Dec 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.